Fertility preservation before neoadjuvant chemotherapy in a premenopausal breast cancer patient: a case report

Arika Kobayashi, Ryoichi Matsunuma*, Kei Yamaguchi, Ryosuke Hayami, Michiko Tsuneizumi and Kazuhiko Nakagami

Department of Breast Surgery, Shizuoka Prefectural Hospital Organization, Shizuoka General Hospital, Shizuoka 420-8527, Japan

*Correspondence address. Department of Breast Surgery, Shizuoka Prefectural Hospital Organization, Shizuoka General Hospital, Shizuoka 420-8527, Japan. Tel: +81-54-247-6111; Fax: +81-54-247-6140; E-mail: r-matsunuma@nifty.com

Abstract

Neoadjuvant chemotherapy is now a widely accepted treatment modality for operable breast cancer and therefore fertility preservation is an important component of care for young patients with breast cancer. It is critical that oocyte retrieval is completed without delays in the initiation of neoadjuvant chemotherapy. Here we report the case of a 34-year-old woman who was diagnosed with Stage IIA triple-negative breast cancer and underwent ovarian stimulation for fertility preservation prior to the initiation of neoadjuvant chemotherapy. Oocytes were retrieved and in vitro fertilization was conducted before neoadjuvant chemotherapy was started. Upon completion of neoadjuvant chemotherapy, the patient underwent breast surgery. Subsequently, a pathological complete response was achieved. She received a frozen embryo transfer 10 months after breast surgery. The patient became pregnant and delivered a healthy baby.

INTRODUCTION

Neoadjuvant chemotherapy is considered the standard care for operable breast cancer patients, particularly, for patients with triple-negative breast cancer, which is defined as no expressions of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) or HER2-enriched subsets, including locally advanced breast cancer. The commonly used neoadjuvant treatment regimens are well-known for their negative impact on fertility. Specifically, this is due to gonadotoxicity, which importantly may lead to premature ovarian failure [1].

Breast cancer patients of reproductive age should have the opportunity for preserving fertility prior to initiating neoadjuvant chemotherapy. Breast oncologists and surgeons should cooperate with fertility specialists without significantly delaying breast cancer treatment.

The following case is important because a collaborative team effort contributed to neoadjuvant chemotherapy start without breast cancer progress and embryo transfer helped her become pregnant and give birth following breast surgery.

CASE REPORT

In May 2016, a 34-year-old woman, gravida 0, para 0, noticed a lump in her right breast. During physical examination, we identified a 2-cm lump in her right upper breast and absence of axillary lymphadenopathy. Diagnostic mammography detected a mass without speculation. Breast ultrasonography revealed...
toward delaying the first pregnancy to 30–40 years of age. To date, for a number of reasons, there is an increasing trend

**DISCUSSION**

To date, for a number of reasons, there is an increasing trend toward delaying the first pregnancy to 30–40 years of age. Reportedly, this tendency is concordant with an increasing incidence of breast cancer in women who have not yet completed their family. Unfortunately, neoadjuvant chemotherapy or adjuvant chemotherapy regimens commonly used in breast cancer treatment can lead to premature ovarian failure due to their cytotoxic effects on germ cells. Therefore, fertility preservation in breast cancer survivors of reproductive age has become an important issue regarding quality of life.

To date, numerous potential options are available, including all available assisted reproductive technologies (i.e. IVF and embryo transfer, in vitro maturation, oocyte and embryo cryopreservation and cryopreservation of ovarian tissue). Currently, embryo cryopreservation represents the most established fertility-preservation strategy. Notably, it provides a 25–35% chance of pregnancy. Additionally, oocyte freezing can be considered an alternative for single parents and for those who do not wish for a sperm donor.

In a systematic review and meta-analysis conducted by Yu et al., the authors found that breast cancer patients should start adjuvant chemotherapy with no more than an 8-week delay from the planned initiation, which is probably within 4 weeks after surgery. Thus it is important for fertility preservation procedures to be performed without causing a significant delay in cancer treatment. For breast cancer patients undergoing neoadjuvant chemotherapy, there is no evidence that a longer time prior to treatment is associated with worse survival. Therefore, the safety and outcome of fertility preservation prior to neoadjuvant chemotherapy should be evaluated from a diagnosis-treatment duration perspective in the future. Letourneau et al. reported that in their retrospective study, the average time from breast cancer diagnosis to chemotherapy start after ovarian stimulation was 38.1 days. However, in the present case, the time from diagnosis to chemotherapy start was 51 days. The reason why there was a delay in this case, compared with Letourneau’s study, was that it took as many as 14 days for our patient to visit the IVF clinic after diagnosis for some reason. Therefore, it is important how quickly patients visit the IVF department or

| Diagnosis and treatment | Results |
|-------------------------|---------|
| Mammography             | Suspicious abnormality |
| Breast ultrasound        | Suspicious abnormality |
| Computed tomography      | No sign of lymph node and distant organs metastases |
| Breast MRI               | Oval, irregular, rim enhancement, 21 × 16 mm |
| Needle biopsy            | Solid-tubular carcinoma |
| Clinical stage           | IIA (T2N0M0) |
| Subtype                  | Triple-negative (ER+, PR+, HER2 1+) |
| Neoadjuvant chemotherapy | FEC followed by docetaxel |
| Surgery                  | Breast-conserving surgery |
| Radiation therapy after surgery | Whole breast to a dose of 50 Gy in 25 fractions |
| Adjuvant systemic therapy | No |

**Table 2: Overview of the clinical course**

| Time course    | Event                  |
|----------------|------------------------|
| Day 0          | First visit            |
| Day 14         | Diagnosis              |
| Day 28         | IVF clinic visit       |
| Day 54         | Oocytes retrieved      |
| Day 65         | Neoadjuvant chemotherapy starts |
| 8 months after first visit | Surgery |
| 10 months after surgery | Embryo transfer |

**Figure 1:** Contrast-enhanced MRI, allowing more detailed information for making the diagnosis of breast cancer, showed a 21-mm mass in the right breast with rim enhancement (left). In the right MRI, there was no sign of breast cancer after neoadjuvant chemotherapy, suggesting a clinical complete response.
clinic with enough information about breast cancer and fertility preservation to receive breast cancer treatment without a significant delay.

Breast cancer patients who receive neoadjuvant chemotherapy tend to have higher recurrence risk than those who do not. However, the range of time for initiation of neoadjuvant chemotherapy may be shorter than the duration from surgery to initiation of adjuvant chemotherapy. As a consequence, a collaborative team effort is required. The ultimate goal is to effectively communicate the pros and cons of the various modalities available, treatment’s effectiveness, the possible long-term risks, the cost of intervention, support in patients’ concerns and treatment planning. Fertility preservation process should start after the diagnosis of breast cancer without a delay in the initiation of neoadjuvant treatment, which becomes a standard care of operable breast cancers.

ACKNOWLEDGEMENTS
We thank the staff and nurses, Dr Fumiko Tawara and the patient.

CONFLICT OF INTEREST STATEMENT
None declared.

FUNDING
There was no financial support.

ETHICAL APPROVAL
No specific ethical approval was required.

CONSENT
Written informed consent was obtained from the patient for the submission of this manuscript.

GUARANTOR
R.M. is the guarantor of this article.

REFERENCES
1. Goodwin PJ, Ennis M, Pritchard KI, Trudeau M, Hood N. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol 1999;17:2365–70 doi: http://dx.doi.org/10.1200/JCO.1999.17.8.2365.
2. Kasum M, Beketic-Oreskovic L, Peddi PF, Oreskovic S, Johnson RH. Fertility after breast cancer treatment. Eur J Obstet Gynecol Reprod Biol 2014;173:13–8 doi: http://dx.doi.org/10.1016/j.ejogrb.2013.11.009.
3. Malamos NA, Statopoulos GP, Keramopoulos A, Papad imantis J, Vassilarios S. Pregnancy and offspring after the appearance of breast cancer. Oncology 1996;53:471–5 doi: http://dx.doi.org/10.1159/000227622.
4. Kalantaridou SN, Davis SR, Nelson LM. Premature ovarian failure. Endocrinol Metab Clin N Am 1998;27:989–1006 doi: http://dx.doi.org/10.1016/S0889-8529(05)70051-7.
5. Oktay K, Buyuk E, Libertella N, Akar M, Rosenwaks Z. Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. J Clin Oncol 2005;23:4347–53 doi: http://dx.doi.org/10.1200/jco.2005.05.037.
6. Reddy J, Oktay K. Ovarian stimulation and fertility preservation with the use of aromatase inhibitors in women with breast cancer. Fertil Steril 2012;98:1363–9 doi: http://dx.doi.org/10.1016/j.fertnstert.2012.09.022.
7. Donnez J, Dolmans MM, Demytle D, Jadoul P, Pirard C, Squifflet J, et al. Live birth after orthotopic transplantation of cryopreserved ovarian tissue. Lancet 2004;364:1405–10 doi: http://dx.doi.org/10.1016/S0140-6736(04)17222-X.
8. Barcroft J, Dayoub N, Thong KJ. Fifteen year follow-up of embryos cryopreserved in cancer patients for fertility preservation. J Assist Reprod Genet 2013;30:1407–13 doi: http://dx.doi.org/10.1007/s10815-013-0024-z.
9. Oktay K, Buyuk E, Rodriguez-Wallberg KA, Sahin G. In vitro maturation improves oocyte or embryo cryopreservation outcome in breast cancer patients undergoing ovarian stimulation for fertility preservation. Reprod Biomed Online 2010;20:634–8 doi: http://dx.doi.org/10.1016/j.rbmo.2010.01.012.
10. Shalom-Paz E, Almog B, Shehata F, Huang J, Holzer H, Chian RC, et al. Fertility preservation for breast-cancer patients using IVM followed by oocyte or embryo vitrification. Reprod Biomed Online 2010;21:566–71 doi: http://dx.doi.org/10.1016/j.rbmo.2010.05.003.
11. Kim SS, Klemm J, Fabian C. Breast cancer and fertility preservation. Fertil Steril 2011;95:1535–43 doi: http://dx.doi.org/10.1016/j.fertnstert.2011.01.003.
12. Yu KD, Huang S, Zhang JX, Liu GY, Shao ZM. Association between delayed initiation of adjuvant CMF or anthracycline-based chemotherapy and survival in breast cancer: a systematic review and meta-analysis. BMC Cancer 2013;13:240 doi: http://dx.doi.org/10.1186/1471-2407-13-240.
13. Letourneau JM, Sinha N, Walld K, Harris E, Quinn M, Imbar T, et al. Random start ovarian stimulation for fertility preservation appears unlikely to delay initiation of neoadjuvant chemotherapy for breast cancer. Hum Reprod 2017;32:2123–9 doi: http://dx.doi.org/10.1093/humrep/dex276.